Buscar
Supernus Pharmaceuticals Inc
SUPNAñadir a la lista de seguimiento
44.630USD
-0.980-2.15%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
2.59BCap. mercado
PérdidaP/E TTM
Más Datos de Supernus Pharmaceuticals Inc Compañía
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Información de Supernus Pharmaceuticals Inc
Símbolo de cotizaciónSUPN
Nombre de la empresaSupernus Pharmaceuticals Inc
Fecha de salida a bolsaDec 28, 2010
Director ejecutivoKhattar (Jack A)
Número de empleados674
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 28
Dirección9715 Key West Avenue
CiudadROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Teléfono13018382500
Sitio Webhttps://www.supernus.com
Símbolo de cotizaciónSUPN
Fecha de salida a bolsaDec 28, 2010
Director ejecutivoKhattar (Jack A)
Ejecutivos de Supernus Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.20M
-2.16%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
60.41K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
27.28K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
27.05K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
18.44K
+3.11%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
17.04K
+4.32%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
13.34K
+4.61%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
8.23K
+8.95%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Peter Vozzo
Mr. Peter Vozzo
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.20M
-2.16%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
60.41K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
27.28K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
27.05K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
18.44K
+3.11%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
17.04K
+4.32%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Supernus Pharmaceuticals Inc?
Los cinco principales accionistas de Supernus Pharmaceuticals Inc son: Mr. Jack A. Khattar
¿Cuántas instituciones poseen acciones de Supernus Pharmaceuticals Inc (SUPN)?
A fecha de 2026Q1, 651 instituciones poseen acciones de Supernus Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 66.06M, lo que representa el 113.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 238896.00.
¿Cuál es la mayor fuente de ganancias de Supernus Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial Net product sales-Qelbree generó la ganancia más alta para Supernus Pharmaceuticals Inc, ascendiendo a 304.65M y representando el 42.37% de la ganancia total.